Literature DB >> 34240678

The costs of treatment resistant depression: evidence from a survey among Italian patients.

Matteo Ruggeri1,2, Carlo Drago3, Donatella Mandolini4, Pier Francesa Morel5, Claudio Mencacci6, Fabrizio Starace7.   

Abstract

INTRODUCTION: Treatment resistant depression (TRD) is a severe form of major depressive disorder associated with high symptoms severity, disability, and health resource utilization. AIM: The purpose of this study is to estimate the coss of TRD in Italy.
METHODS: The study was carried on a sample of Italian patients diagnosed with TRD in 2019. In total, 306 observations were collected. The first step was to estimate the health and social costs of TRD resulting from the survey applying the Italian tariffs, daily wages, and prices. Secondly, we focused on the determinants of out of pocket expenditure (OOPE). A parametric analysis was performed to explore the association between the costs of TRD and a set of co-variates.
RESULTS: In total, the average healthcare costs were €2,653. A national average of 42 lost working days was estimated resulting in a total cost of €7,140 per patient. Regarding OOPE an average of € 615 per patient was found. Regression results showed how relevant regional gradients are likely to affect the amount of OOPE for TRD.
CONCLUSIONS: the study confirms the important burden of TRD in Italy with specific focus on out of pocket expenditure. High heterogeneity is shown concerning regional settings.

Entities:  

Keywords:  Treatment resistant depression; cost of illness; health direct costs; out of pocket expenditure; productivity losses

Mesh:

Year:  2021        PMID: 34240678     DOI: 10.1080/14737167.2021.1954507

Source DB:  PubMed          Journal:  Expert Rev Pharmacoecon Outcomes Res        ISSN: 1473-7167            Impact factor:   2.217


  3 in total

1.  Pharmacogenomics-Guided Pharmacotherapy in Patients with Major Depressive Disorder or Bipolar Disorder Affected by Treatment-Resistant Depressive Episodes: A Long-Term Follow-Up Study.

Authors:  Antonio Del Casale; Leda Marina Pomes; Luca Bonanni; Federica Fiaschè; Clarissa Zocchi; Alessio Padovano; Ottavia De Luca; Gloria Angeletti; Roberto Brugnoli; Paolo Girardi; Robert Preissner; Marina Borro; Giovanna Gentile; Maurizio Pompili; Maurizio Simmaco
Journal:  J Pers Med       Date:  2022-02-19

2.  Helicid Improves Lipopolysaccharide-Induced Apoptosis of C6 Cells by Regulating SH2D5 DNA Methylation via the CytC/Caspase9/Caspase3 Signaling Pathway.

Authors:  Yuan Zhang; Mei Wang; Xiaotong Zhang; Zhenyi Jiang; Yuanxiang Zhang; Xiangjun Fu; Yanna Li; Danping Cao; Jun Han; Jiucui Tong
Journal:  Contrast Media Mol Imaging       Date:  2022-01-31       Impact factor: 3.161

3.  Economic burden of major depressive disorder: a case study in Southern Iran.

Authors:  Khosro Keshavarz; Arvin Hedayati; Mojtaba Rezaei; Zahra Goudarzi; Ebrahim Moghimi; Mehdi Rezaee; Farhad Lotfi
Journal:  BMC Psychiatry       Date:  2022-08-30       Impact factor: 4.144

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.